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Edited by Christian GriesingerAbstract With the aim of elucidating the biological function of
hypothetical proteins unique amongst the Actynomyces sub-
group of bacteria, we have solved the crystal structure of the
conserved hypothetical protein Rv1155 from Mycobacterium
tuberculosis at 1.8 A˚ resolution. Rv1155 is a homodimer both
in the crystal structure and in solution and folds into two sepa-
rate domains consisting of a six-stranded anti-parallel b-barrel
fold ﬂanked by two a-helices and a helix-turn-helix domain. Both
domains contribute to the formation of two deep clefts at the di-
mer interface. The overall fold of Rv1155 strikingly resembles
that of ﬂavin mononucleotide-binding protein and pyridoxamine
5 0-phosphate oxydase, but the architecture of the putative bind-
ing pocket is markedly diﬀerent, consistent with the lack of color
of Rv1155 and its inability to bind FMN. Rv1155 thus appears to
belong to a group of proteins with stringent conservation of the
binding cleft, having evolved towards a new binding function.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Tuberculosis is one of the most devastating bacterial diseases
and kills two to three million people around the world each
year. It is further estimated that around one-third of the
worlds population will be infected as a result of ability of
the organism to persist for many years in a semidormant or la-
tent form inside activated macrophages [1]. In addition, cur-
rent therapies are long and diﬃcult and multidrug resistance
has appeared, resulting in a resurgence of interest from the sci-
entiﬁc community to unveil factors responsible for the patho-Abbreviations: FMN, ﬂavin mononucleotide; FMN-bp, FMN-binding
protein; PNPOx, pyridoxamine 5 0-phosphate oxydase
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doi:10.1016/j.febslet.2004.11.069genicity of this organism. Most importantly, the unusual
ability of M. tuberculosis to persist in the host for long periods
of time suggests that mycobacteria may use unique pathogenic
mechanisms, possibly involving speciﬁc proteic factors, com-
pared to other common bacterial pathogens.
The sequence information of theM. tuberculosisH37Rv gen-
ome has considerably increased our knowledge about the pro-
tein families that are present in mycobacteria [2]. The 4000
gene products have been classiﬁed into 11 functional groups
but a known or putative function can be assigned at the se-
quence level for only 52% of those, while only a few 150 have
been experimentally characterized in mycobacteria [3,4].
Therefore, the remaining 48% of the gene products, which con-
sist of conserved hypothetical proteins belonging to the func-
tional class 11, remain to be fully investigated. More
recently, 194 gene products were found to be essential for
mycobacteria survival in vivo [5]; 30% of these have yet un-
known function, an observation that emphasizes structure-
function relationship studies of these conserved hypothetical
proteins.
We are attempting to solve new crystal structures of proteins
from M. tuberculosis that are exclusively distributed in myco-
bacteria as well as amongst the Actinomycetes sub-group of
bacteria. To this aim, we have focused our attention on 95 con-
served hypothetical proteins that were selected based on solu-
bility criteria as detected by bio-informatic analyses out of 376
proteins that are unique to the Actinomycetes sub-group of
bacteria based on currently available genomes [4]. Currently,
no three-dimensional structure is available for this class of pro-
teins in M. tuberculosis.
In order to shed light on its function by revealing possible
homologies that cannot be detected at the sequence level, we
have determined the crystal structure of Rv1155 at 1.8 A˚ reso-
lution. Rv1155 is a conserved hypothetical protein of 147 res-
idues with a theoretical molecular weight of 16.3 kDa and a
pI value of 6.5. The amino acid sequence of Rv1155 has no
detectable homology with any other proteins of known struc-
ture, but its three-dimensional structure unambiguously re-
veals that Rv1155 is structurally related to the large family
of ﬂavin mononucleotide-binding protein (FMN-bp), includ-
ing pyridoxamine 5 0-phosphate oxydase (PNPOx). In fact,
Rv1155 not only shares a two-domain b-barrel fold organiza-
tion as seen for members of this family but also the dimeric
assembly that characterizes PNPOx. At the dimer interface, a
large cleft is lined with conserved residues that may have bio-
logical implications in Rv1155. Consequently, the presence of
these functional consensus motifs within close homologs ofblished by Elsevier B.V. All rights reserved.
216 S. Canaan et al. / FEBS Letters 579 (2005) 215–221Rv1155 permitted the identiﬁcation of a new family of
Rv1155-like proteins that is structurally related to FMN-bp
and PNPOx but does not bind FMN as demonstrated by ﬂuo-
rescence titration.2. Materials and methods
2.1. Construction of the His-pKM596-Rv1155 expression vector
The open reading frame encoding for Rv1155 was ampliﬁed by PCR
from the MTCI65 cosmid [3,6] using the forward primer 5 0-cggaaa-
acctgtacttccagggtGCCCGCCAAGTCTTCGACGAC- 3 0 (TEV cleav-
age site is underlined) and the reverse primer 5 0-TTAGCGCATAC-
CGGGCGGCAG-3 0 containing the attB1 and attB2 recombination
sites at the 5 0and 3 0 end, respectively. The PCR product was ﬁrst
cloned into the pDONR 201 plasmid and subsequently into the expres-
sion vector His-pKM596 [7,8], following the manufacturers protocol
(Gateway, Invitrogen). The presence of a TEV site between His6-
MBP and Rv1155 allowed release of recombinant Rv1155 after
proteolysis.
2.2. Expression and puriﬁcation of recombinant Rv1155
Escherichia coli BL21 pLys S (Novagen) cells were transformed with
the His-pKM596-Rv1155 plasmid and cultured overnight in LB broth
with 100 lg/ml ampicillin and 34 lg/ml chloramphenicol. The culture
was diluted 20-fold with minimal M9 medium and grown at 37 C.
Protein expression was induced with 0.5 mM isopropyl b-D-thiogalac-
toside (IPTG) when the OD600 had reached a value in the 0.6–0.8
range. At the moment of induction, L-selenomethionine and aminoac-
ids known to inhibit methionine biosynthesis were added [9]. Cells were
harvested after 16 h, resuspended in lysis buﬀer (50 mM Tris–HCl, pH
8.0, 150 mM NaCl, 10 mM imidazole, 1 mM EDTA, 0.1% Triton X-
100, 0.25 mg/ml lysozyme and 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF)) and stored at 80 C. The frozen cells were thawed on ice be-
fore incubation for 30 min with 10 lg/ml DNAse and 20 mM MgSO4
(ﬁnal concentration). Cells were disrupted by ultrasonication and cell
debris were removed by centrifugation. Rv1155 was puriﬁed by Ni2+
aﬃnity and size exclusion chromatographies in buﬀer made of 5 mM
HEPES, pH 7.5, and 150 mM NaCl. Rv1155 was cleaved from the
MBP fusion by TEV digestion and puriﬁed by exclusion on a Ni2+
aﬃnity column, taking advantage of the presence of the 6His tag on
the MBP N-terminus. Puriﬁed Rv1155 was further characterized by
circular dichroism and dynamic light scattering and SeMet incorpora-
tion was veriﬁed by MALDI-TOF mass spectroscopy. SeMet-labeled
Rv1155 was concentrated up to 5.7 mg/ml and stored at 80 C.
2.3. FMN-binding assay
Fluorometry data were acquired using a Cary Eclipse Fluorescence
Spectrophotometer (Varian) and analyzed using the Cary Eclipse soft-
ware. Emission spectra were generated using an excitation wavelength
of 450 nm. Quenching of FMN ﬂuorescence was determined from the
ﬂuorescence emission integrated over the 470–650 nm wavelength
range. Standard assay conditions were measured at room temperature
with 2 lM of FMN (Sigma) incubated with various amounts of
Rv1155 (0.3–15 lM) in 1 ml of buﬀer solution (5 mM HEPES, pH
7.5, and 150 mM NaCl). Measurements were also performed in func-
tion of time (0 and 24 h). Flavodoxin from Desulfovibrio vulgaris was
used as a positive control. Brieﬂy, apo-ﬂavodoxin was puriﬁed as de-
scribed previously [10] and bound FMN was completely removed by
mixing cold trichloroacetic acid (10% w/v) to the protein solution in
5 mM HEPES, pH 7.5, and 150 mM NaCl (buﬀer A) at 4 C. After
centrifugation, the precipitate was dissolved in buﬀer A and this pro-
cedure was repeated once; traces of trichloroacetic acid were removed
by dialyzing overnight against the same buﬀer. Protein concentration
was estimated using the Bradford assay.2.4. Crystallization and X-ray data collection
Initial crystals of Rv1155 were obtained at room temperature from
solution 21 of the Wizard I crystallization screen (Emerald Biostruc-
tures) using our automated crystallization facility [11]. Larger crystals
of the SeMet-labeled Rv1155 were grown using the hanging drop
method by mixing 1 ll of protein solution with 1 ll of precipitant solu-tion consisting of 0.1 M HEPES, pH 7.5, and 14–16% PEG 6 K. Thin
plate crystals grew within 5–6 days. Crystals were transferred to a cryo-
protectant solution consisting of reservoir solution supplemented with
30% (v/v) ethylene glycol and ﬂash frozen in a nitrogen gas stream at
100 K. Crystals belong to the monoclinic space group P21 with cell
dimensions a = 46.9 A˚, b = 55.1 A˚, c = 55.2 A˚ and b = 108.3. Assum-
ing two monomers per asymmetric unit, the Vm value is 2.1 A˚
3/Da cor-
responding to 41% solvent. A 3-wavelength multiple-wavelength
anomalous dispersion (MAD) data set was collected up to 1.8 A˚ reso-
lution on the SLS beam line X06SA (Switzerland). Data were inte-
grated with DENZO [12] and scaled and merged with SCALA [13].
2.5. Structure determination and reﬁnement
Initial phases were obtained using SOLVE [14] that located the four
Se atoms present in the asymmetric unit. The initial MAD phases were
improved by solvent ﬂattening and non-crystallographic symmetry
averaging using RESOLVE at 1.8 A˚ resolution [15] and an initial
model consisting of 242 out of the 289 residues present in the ﬁnal
model was automatically traced. Further manual rebuilding was done
with the graphics program TURBO-FRODO [16] and reﬁnement was
carried out with REFMAC [17]. Solvent molecules were automatically
added using ARP/wARP [18]. The ﬁnal model consists of residues
Phe6 to Arg147 and Val5 to Arg147 for each of the two subunits pres-
ent in the asymmetric unit. The stereochemistry of the ﬁnal model was
veriﬁed with PROCHECK [19]. The r.m.s.d. value between the two
subunits is 0.8 A˚ for 115 Ca atoms. Data collection, reﬁnement and
structure quality statistics are shown in Table 1. Coordinates of Se-
Met-labeled Rv1155 have been deposited in the Protein Data Bank,
with Accession No. 1W9A. Figures were produced with PyMOL [20].3. Results and discussion
3.1. Cloning, expression and puriﬁcation
Attempts to express Rv1155 as a soluble protein using the
pDEST 17 expression vector (Gateway, Invitrogen) were
unsuccessful. To overcome this problem, the gene was inserted
downstream of various fusion proteins (MBP, Trx, GST and
NusA) known to favor the expression of soluble proteins in
E. coli [21]. As a result, large amounts of Rv1155 could be ex-
pressed in soluble form using the MBP and Trx fusion con-
structs, but release of Rv1155 using the TEV protease was
more eﬃciently achieved from the MBP fusion protein. Fur-
ther characterizations were assessed by circular dichroism
and dynamic light scattering and have shown that Rv1155 is
a monodisperse a/b protein in solution (data not shown).
The overall yield of puriﬁed SeMet-labeled Rv1155 after
TEV cleavage is 1.9 mg/L of culture medium, corresponding
to 60% of the cleaved MBP fusion protein.3.2. Structure quality and overall monomer fold
The crystal structure of Rv1155 was solved using the MAD
method from the Se anomalous signal. The excellent quality of
the 1.8 A˚ resolution experimental electron density maps per-
mitted to build automatically 242 residues, out of the 289 pres-
ent in the ﬁnal model, that were subsequently reﬁned against
data collected at the remote energy wavelength (Table 1).
The ﬁnal model, which has good stereochemistry, consists of
residues Val5/Phe6 to Arg147 for each of the two subunits
present in the asymmetric unit and 371 solvent molecules.
A Rv1155 subunit is folded into two separate domains. The
larger domain (domain 1) encompasses two discontinuous re-
gions formed by residues Phe6 to Pro90 and Arg128 to
Arg147 and consists of a central curved six-stranded anti-par-
allel b-barrel (b1 to b6) ﬂanked by two helices (a1,a2). The
smaller domain (domain 2), which is composed of residues
Table 1
Data collection and reﬁnement statistics
Peak (Se) Inﬂection (Se) Remote (Se)
Data collection
Beam line SLS-X06
Wavelength (A˚) 0.97904 0.97924 0.95373
Space group P21
Cell dimensions (A˚) a = 46.9, b = 55.1, c = 55.3; b = 108.2
Molecule/A.U. 2
Resolution range (A˚)a 38–1.8 (1.85–1.80)
Rmerge (%)
b 4.5 (20.2) 4.6 (24.5) 4.4 (21.3)
Ranom (%)
c 5.4 (18.7) 4.4 (21.7) 4.2 (18.7)
No. of observations 77280 76481 79478
No. of unique reﬂections 24110 24135 24197
Completeness (%) 97.1 (93.8) 97.1 (94.2) 97.4 (95.0)
Redundancy 3.2 (3.2) 3.2 (3.1) 3.3 (3.2)
ÆI/rIæ 19.2 (5.1) 18.7 (4.4) 20.0 (4.7)
B from Wilson plot (A˚) 16.0 16.8 16.5
Reﬁnement
Resolution range (A˚) 20–1.8 (1.85–1.80)
Protein/solvent atoms 2301/371
Rcryst=Rfree (%) 14.1 (17.2)/17.5 (22.0)
Average B main/side/solvent (A2) 14.7/17.3/31.2
Rms deviations
Bond distances (A˚) 0.011
Bond angles () 1.28
Chiral volume (A3) 0.08
Main/side chain DB (A2) 0.56/1.67
Ramachandran outliers None
aValues in parentheses are for the highest resolution shell.
bRmerge ¼
P
hkl
P
ijIhkli  hIhkliij=
P
hkl
P
ihIhklii.
cRanom ¼
P jhIþi  hIij=PðhIþi þ hIiÞ.
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inserted between b5 and b6 and is located opposite to the con-
cave face of the central b-sheet (Fig. 1). Helix 4 within domain
2 lies almost perpendicular to the direction of strands b2, b3
and b5 in domain 1 and largely participates to the domain
interface. Indeed, helix 4 residues Thr99, Leu103, Leu106
and Ile110 tightly interact with Thr89, Ser50, Leu131, Gln48
and His39 from the central b-sheet.
3.3. Dimeric assembly
Two Rv1155 subunits associate in the asymmetric unit of the
crystal to form a tight dimer that adopts an elongated shape
with dimensions of 60 A˚ · 35 A˚ · 35 A˚ (Fig. 1). This dimeric
assembly is consistent with the apparent molecular size of
31.6 kDa obtained by gel ﬁltration (data not shown) and thus
may reﬂect the biological assembly of Rv1155 in solution. The
dimer interface, which buries 1350 A˚2 to a 1.6 A˚ probe radius
on each subunit, involves 20 conserved residues located with-
in strands b1, b2, b4 and b5 located on the concave face of the
b-barrel. In contrast, residues within each of the two domains
2 do not contribute to dimer stabilization, since these domains
are projected away from each extremity of the dimer interface
and are distant by 50 A˚.
3.4. Putative ligand binding site
The molecular surface of Rv1155 evidences a curve-shaped
cleft, 6 A˚ deep and 25 A˚ long, as a possible functional ligand
binding site built up by charged and polar residues from both
subunits. The bottom of the binding cleft is entirely deﬁned by
residues from strand b2, while distinct arrays of residues formthe lateral walls of the cleft (Fig. 1). Residues within the b3–b4
loop in domain 1 and the two a3 and a4 helices in domain 2
are recruited to form one wall, while the opposite wall is made
with residues in strand b6 from the second subunit. While the
section of the cleft is rather narrow near the dimer interface, its
volume signiﬁcantly increases at the domain junction to form a
larger binding pocket. It is likely that Ser50 that lies at the bot-
tom of the pocket may have an important role for ligand rec-
ognition. Other residues protruding into the cleft and thus
likely to be crucial for ligand binding are Gln37, Arg55,
Lys57 and Thr58 within domain 1 along with residues
Tyr107, His114, Asp119, Tyr120, Met124, Asp127 and
Arg129 within domain 2 on one side of the cleft and residues
Trp77, Tyr79, Tyr140, and Arg147 from the second subunit
at the opposite wall of the binding cleft. Interestingly, these lat-
ter residues located in the b4–b5 loop and at the very C-termi-
nus, respectively, undergo a concerted motion in one subunit
with respect to the other, leading to remarkable structural dif-
ferences at one side of the cleft. This, together with an inter-do-
main motion of 10 of the small domain 2 relative to domain 1,
rendering one of the binding clefts more narrow than the
other, leads to speculate that a considerable conformational
ﬂexibility exists in solution.
3.5. Structural comparison
A DALI search for close structural homologs of Rv1155
within a non-redundant set of protein structures from the
PDB revealed top-ranked hits for the FMN-binding proteins
(D. vulgaris FMN-bp) (Accession No. 1AXJ [22], Z score value
9.5, r.m.s.d. of 3.0 A˚ for 107 Ca atoms), the PNPOx from Sac-
Fig. 1. Overall fold of Rv1155. (A) Ribbon diagram of the dimer
viewed along the approximate twofold axis with domain 1 from the
two subunits shown in cyan and yellow, while the two domains 2 are
shown in green. The b4–b5 loop and the C-terminal region are shown
in orange. The secondary structure elements are indicated. (B) View
oriented 90 from (a) and colored as in (a) showing the large cleft at the
dimer interface through a transparent molecular surface in the left
subunit.
Fig. 2. Structural comparison. (A) Ribbon diagram of the D. vulgaris
FMN-bp (Accession No. 1AXJ) with bound FMN (magenta) showing
a single conformer (model 1) out of 20 and oriented and colored as the
left subunit in Fig. 1A. (B) Ribbon diagram of the S. cerevisiae PNPOx
dimer (Accession No. 1CI0) with bound FMN (magenta) with the
central b-sheet of the left subunit oriented and colored as in Fig. 1A.
The additional regions in PNPOx compared to Rv1155 and FMN-bp
are shown in red, while those that signiﬁcantly diﬀer between Rv1155,
FMN-bp and PNPOx are indicated in orange. In the left subunit, the
FMN-binding site at the dimer interface is shown through a
transparent molecular surface.
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volved in the de novo synthesis of pyridoxine (vitamin B6)
and pyridoxal phosphate. Although these proteins share a sim-
ilar structural topology, Rv1155 displays only 19% and 11%
sequence identities with FMN-bp and PNPOx, respectively.
FMN-bp represents the smallest FMN-binding protein known
to date with only 122 amino acid residues compared to 205 res-
idues found in PNPOx. Whereas the core of the b-barrel made
of six b-strands is well conserved between these proteins, the
largest structural diﬀerences reside in the overall architecture
of domain 2, which consists of 15 and 55 residues in FMN-
bp and PNPOx, respectively, compared to 37 in Rv1155
(Fig. 2). In domain 1, the conformations of the a1–b1 loop
and the two b1–b2 and b3–b4 loops forming the FMN-binding
site in FMN-bp and the corresponding loop regions in PNPOx
are also markedly diﬀerent in Rv1155.
Whereas FMN-bp is monomeric in solution [22], Rv1155
shares the dimeric assembly that characterizes members of
the PNPOx family, for which three-dimensional structures
have been determined so far for E. coli [23], human [24] and
yeast enzymes (unpublished data, PDB 1CI0) (Fig. 2). In addi-
tion to the structural diﬀerences identiﬁed between Rv1155 and
FMN-bp, members of the PNPOx family are characterized by
the extension of 10 and 25 residues in the N- and C-terminal
region, respectively. Consequently, the size of the dimer inter-face is signiﬁcantly larger in PNPOx compared to Rv1155 (Fig.
2).
In both FMN-bp and PNPOx, the FMN ligand is tightly
bound within a shallow cleft located between b2 and the loop
connecting b3–b4 as found in Rv1155. Moreover, there are
numerous FMN- and phosphate-mediated hydrogen bonds
linking the two PNPOx monomers, suggesting a similar sce-
nario for Rv1155, where conserved residues from both sub-
units might have an important role in ligand recognition.
The fact that only a single residue (PNPOx Arg95/FMN-bp
Lys53) in contact with FMN is conserved between D. vulgaris
FMN-bp and S. cerevisiae PNPOx indicates that FMN does
not require speciﬁc signature motifs and is thus able to be
accommodated by diverse proteins. However, a structural
overlap evidences several clashes between the FMN isoalloxa-
zine ring of both FMN-bp and PNPOx and the Rv1155
conserved residues Trp77, Tyr79 in the b4–b5 loop and the
C-terminal Arg147, suggesting that Rv1155 may lack the abil-
ity to bind to FMN or the related FAD and riboﬂavin
compounds.
While the shape of the FMN-binding site in PNPOx is fun-
nel-like, the architecture of the putative ligand binding site in
Rv1155 resembles a deep cleft and is thus more accessible to
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shape of the binding site is mainly due to the presence of a
shorter domain 2 combined with the lack of the two last b-
strands in FMN-bp and Rv1155 compared to PNPOx (Fig.
2). To validate our structural interpretation, we have explored
the ability of CASTp (http://cast.engr.uic.edu/cast) to auto-
matically identify surface pockets as putative ligand binding
sites [25]. CASTp successfully identiﬁed the shallow pocket lo-
cated at the dimer interface of Rv1155. This pocket has a sur-
face area of 780 A˚2 and a volume of 1573 A˚3, consistent with
the size of the FMN-binding pocket (1300 and 1812 A˚3) previ-
ously identiﬁed from crystallographic analysis of PNPOx and
in agreement with the diﬀerences observed for the architecture
of the cavity between these two protein families. Altogether,
these observations support the idea of a sequence divergence
of residues forming the binding cleft in Rv1155, leading to a
new speciﬁcity for a yet unknown ligand.
3.6. A new family of Rv1155-like proteins with no FMN-binding
activity
As expected, BLAST searches using the Rv1155 sequence as
a template identiﬁed top-ranked homologs with e-values in the
1080 range exclusively within mycobacteria species while oth-
ers, with e values in the 1040 range, were only found in two
Streptomyces species (S. coelicolor and S. avermitilis) and inFig. 3. Sequence alignment of members of the Rv1155-like protein famil
Mycobacterium bovis (Mb1186), Mycobacterium avium (AAS04947), Mycoba
radiotolerans (contig-3273), S. avermitilis (SAV1780) and S. coelicolor (SC
(Rv1875) and S. coelicolor (SCO4026, putative ATP binding protein), respecti
proteins are highlighted with a black background and a boxed area, respec
sequences. Residues that are lining either the dimer interface, the putative liga
respectively.the Kineococcus radiotolerans bacteria. Overall, these close
Rv1155 homologs have sequence identities in the 52–91%
range. The sequence alignment clearly indicates that invariant
residues are conﬁned at the dimer interface and within the cleft
(Fig. 3), consistent with our hypothesis on the importance of
the dimeric assembly and the large cleft for the biological func-
tion of Rv1155. In addition, Rv1155 shares 27% of sequence
identity with another conserved hypothetical protein from
M. tuberculosis, Rv1875, that also shares all the putative func-
tional residues identiﬁed in the binding cleft of Rv1155 (Fig.
3). Surprisingly, Rv1155 shows a signiﬁcant homology with a
putative ATP/GTP-binding protein from S. coelicolor
although the P-loop motif [AG]-X(4)-G-K-[ST] (PROSITE
pattern PS00017) that directly interacts with one of the ATP/
GTP phosphate groups is not conserved in Rv1155, suggesting
that Rv1155 is unable to bind to ATP or GTP. Two other M.
tuberculosis gene products, Rv0121c and Rv2074, have also
been annotated as putative homologs of Rv1155 in the Tuberc-
ulist database (http://genolist.pasteur.fr/TubercuList), but,
again, these two homologs do not possess the key functional
residues of Rv1155 and may have thus a distinct biological
function.
Although Rv1155 has been annotated as a conserved hypo-
thetical protein, searches within the Pfam database unambigu-
ously identiﬁed residues Phe6 to Ala93 from domain 1 whichy. Alignment of M. tuberculosis Rv1155 with close orthologs from
cterium leprae (ML1508), Mycobacterium smegmatis (contig-3563), K.
O5312). The sequences of two related proteins from M. tuberculosis
vely, are also indicated. Invariant and conserved residues between these
tively. Secondary structure elements of Rv1155 are shown above the
nd binding site or both are indicated underneath by (m), (d) and (H),
Fig. 4. FMN-binding assay. (left panel) Rv1155 was incubated with FMN (2 lM) at 0.38 lM (j), 3.8 lM (m) and 19 lM (·) and without FMN (r).
(right panel) For control, D. vulgaris FMN-bp was used at 0.303 lM (j), 1.818 lM (m), 6.363 lM (·), 9.393 lM (d),12.423 lM (+), 15.453 lM ()
and without FMN (r). Data were recorded immediately and 24 h later after mixing FMN and the protein solution.
220 S. Canaan et al. / FEBS Letters 579 (2005) 215–221belong to the PNPOx family (Accession Nos. PF01243,
COG0259), consistent with our structural analysis. However,
a structural alignment between Rv1155 and members of this
Pfam family clearly indicates that a large number of key resi-
dues for binding FMN are not conserved in Rv1155 (see
above), suggesting that Rv1155 may have thus evolved to-
wards a diﬀerent biological function. Such diversity within
the large FMN-bp family has been recently extended with
the identiﬁcation of WrbA, a protein of yet unknown function
in E. coli, that shows a weak but speciﬁc FMN-binding activity
associated to a marked sequence divergence within the a/b fold
[26]. We thus sought to detect a possible interaction between
Rv1155 and FMN in solution by ﬂuorescence titration. In con-
trast to D. vulgaris FMN-bp, Rv1155 is not able to bind FMN
since no signiﬁcant quenching between FMN and various
amounts of Rv1155 could be observed (Fig. 4) (see Section 2).4. Conclusion
Recent proteomic studies combining two-dimensional elec-
trophoresis and mass spectrometry have shown that Rv1155 is
expressed in the cellular fraction of the M. tuberculosis H37Rv
strain [27,28], indicating that this conserved hypothetical pro-
tein may have a functional role in vivo. Therefore, with our
structural information, it would now be interesting to identify
the nature of the ligand of Rv1155 in order to assess the biolog-
ical function of these Rv1155-like proteins in mycobacteria.
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